top of page
  • Recruiting

NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant

Updated: Feb 6


NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant



mrd-clonoseq

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant


The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).


Minimal Residual Disease (MRD) testing by Clonoseq will be performed in the peripheral blood of the patients at the same time points that MRD testing will be done in the bone marrow in addition to at 6 and 18 months.


Sponsor:

H. Lee Moffitt Cancer Center and Research Institute


Adaptive Biotechnologies

 

ClinicalTrials.gov Identifier: NCT05172596


Official Title: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

First Posted : March 9, 2022


Click here to see details on ClinicalTrials.gov

 

Other: Autologous Stem Cell Transplant

Drug: Immunomodulatory Agent

Drug: Proteasome Inhibitor

 

Location:


United States, Florida

Moffitt Cancer Center

Tampa, Florida, United States, 33612





Comments


Posts Archive
bottom of page